PC-407, a celecoxib derivative, inhibited the growth of colorectal tumor in vitro and in vivo

Cancer Science

Volumn 100, Issue 12, 2009, Pages 2451-2458

  Li, Yuhua ^a   Niu, Yinbo ^b   Wu, Huanjie ^a   Zhang, Bangle ^a   Sun, Yang ^a   Huang, Haitao ^a   Li, Qian ^a   Fan, Lei ^a   Liu, Li ^a   Mei, Qibing ^a,b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b NORTHWESTERN POLYTECHNICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

(4 [5 NAPHTHYL 3 (TRIFLUOROMETHYL) 1H PYRAZOL 1 YL] BENZENESULFONAMIDE); CELECOXIB; CYCLOOXYGENASE 2; MESSENGER RNA; PC 407; PROSTAGLANDIN E2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; COLORECTAL TUMOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE ACTIVITY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IMMUNOREACTIVITY; LARGE INTESTINE CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; HT29 CELLS; HUMANS; MALE; MICE; MICE, INBRED ICR; NAPHTHALENES; PHOSPHORYLATION; PYRAZOLES; SULFONAMIDES;

EID: 70649107675     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01335.x     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. Lu B, Zhang ZQ. Novel colon-specific microspheres with highly dispersed hydroxycamptoth- ecin cores: their preparation, release behavior, and therapeutic efficiency against colonic cancer. J Pharm Sci 2006, 95:2619-30.
3. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003, 53:5-26.
4. Farrow DC, Vaughan TL, Hansten PD. Use of aspirin and other nonsteroidal anti-infl amatory drugs and risk of esophageal and gastric cancers. Cancer Epidemiol Biomarkers 1998, 7:97-102.
5. Gaut ZN. Aspirin use and risk of fatal cancer. Cancer Res 1993, 53:1322-7.
6. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol Suppl 1997, 49:6-8.
7. Sandler RS, Halabi S, Baron JA. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003, 348:883-90.
8. Baron JA, Cole BF, Sandler RS. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003, 348:891-9.
9. Zhang BL, Mei QB, He W, Zhou SY. Synthesis of celecoxib. Chin J New Drug 2002, 11:859-61.
10. Zhang BL, Mei QB, Zhou SY, He W, Chen CS. Quantitative structure-activity relationship of the 1, 5-diarylpyrazole class of cyclooxygenase-2 selective inhibitors. J Fourth Milit Med Univ 2003, 24:1523-5.
11. Bai H, Zhang BL, Li YH. Therapeutic effects of selective cyclooxygenase-2 inhibitor PC407 on 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats. World J Gastroenterol 2008, 16:1287-93.
12. Lu ZH, Xiong XY, Zhang BL. Evaluation of 2 celecoxib derivatives: analgesic effect and selectivity to cyclooxygenase-2/1. Acta Pharmacol Sin 2005, 26:1505-11.
13. Jolly K, Cheng KK, Langman MJ. NSAIDs and gastrointestinal cancer prevention. Drugs 2002, 62:945-56.
14. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBios RN. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 2000, 60:6045-51.
15. Li HL, Zhang HW, Chen DD, Zhong L, Ren XD, St-Tu R. JTE-522, a selective COX-2 inhibitor, inhibits cell proliferation and induces apoptosis in RL95-2 cells. Acta Pharmacol Sin 2002, 23:631-7.
16. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107:1183-8.
17. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998, 58:362-6.
18. Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF, Gores GJ. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology 2002, 35:552-9.
19. Lin MT, Lee RC, Yang PC, Ho FM, Kuo ML. Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. J Biol Chem 2001, 276:48997-9002.
20. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000, 30:3-21.
21. Chinery R, Coffey RJ, Graves-Deal R. Prostaglandin J2 and 15-deoxy-delta12, 14-prostaglandin J2 induce proliferation of cyclooxygenase-depleted colorectal cancer cells. Cancer Res 1999, 59:2739-46.
22. Kakiuchi Y, Tsuji S, Tsujii M. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res 2002, 62:1567-72.
23. Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J, Yang WK. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2 selective inhibitor, etodolac. Int J Cancer 2001, 91:894-9.
24. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997, 94:3336-40.
25. Tomozawa S, Tsuno NH, Sunami E. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000, 83:324-8.
26. Liu XH, Kirschenbaum A, Yao S. Upregulation of vascular endothelial growth factor by cobalt chloride-simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line. Clin Exp Metastas 1999, 17:687-94.
27. Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Curr Med Chem 2000, 7:1163-70.
28. Schiffmann S, Maier TJ, Wobst I. The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol 2008, 76:179-87.
29. Drewinko B, Yang LY, Leibovitz A. Cellular discriminants for a biological classification of human colon carcinoma. Cancer Res 1984, 44:4241-53.
30. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000, 275:11397-403.
31. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001, 15:2742-4.
32. Arico S, Pattingre S, Bauvy C. Celecoxibinduces apoptosis by inhibiting 3-phosphoinosi- tide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 2002, 277:27613-21.
33. Wun T, McKnight H, Tuscano JM. Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leuk Res 2004, 28:179-90.
34. Nam DH, Park K, Park C. Intracranial inhibition of glioma cell growth by cyclooxygenase -2 inhibitor celecoxib. Oncol Rep 2004, 11:263-8.
35. Dandekar DS, Lopez M, Carey RI, Lokeshwar BL. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer 2005, 115:484-92.
36. Jendrossek V, Handrick R, Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J 2003, 17:1547-9.
37. Narayanan BA, Condon MS, Bosland MC, Narayanan NK, Reddy BS. Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s). Clin Cancer Res 2003, 9:3503-13.
38. Catalano A, Graciotti L, Rinaldi L. Preclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention. Int J Cancer 2004, 109:322-8.
39. Tuynman JB, Vermeulen L, Boon EM. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. Cancer Res 2008, 68:1213-20.
40. Maier TJ, Janssen A, Schmidt R, Geisslinger G, Grösch S. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. FASEB J 2005, 19:1353-5.